drugset / Trial / NCT00894686

Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)

NCT00894686 ↗

Phase 4 Completed 179 enrolled Pfizer
Non-randomizedOpen-labelPrevention

Summary

The main purpose of this study is to assess the seropersistence of TBE virus antibodies in children, adolescents and young adults who received the first booster vaccination with either FSME-IMMUN 0.25 mL Junior or FSME-IMMUN 0.5 mL in precursor Study 700401.

Timeline

Start
2009-04-26
Primary completion
2017-05-10
Completion
2017-05-10

Drugs

EvaluationDrugModalityDoseRoute
Subject FSME-IMMUN Vaccine 0.25 ml Intramuscular
Subject FSME-IMMUN Vaccine 0.5 ml Intramuscular